Kiniksa Pharmaceuticals is developing targeted therapies for inflammatory and autoimmune conditions, utilizing immune-modulating assets to address critical therapeutic needs. The company focuses on providing effective treatment options for patients suffering from debilitating diseases, such as recurrent pericarditis, where timely intervention is essential.
Funding
$80M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients suffering from inflammatory and autoimmune conditions, such as recurrent pericarditis, often face limited treatment options and significant unmet therapeutic needs. These conditions can be debilitating, requiring timely and effective intervention to manage symptoms and prevent recurrence.
Solution
Kiniksa Pharmaceuticals is focused on developing and commercializing targeted therapeutics for patients with unmet medical needs in inflammatory and autoimmune diseases, with a primary focus on cardiovascular indications. Their lead product, ARCALYST® (rilonacept), is approved for recurrent pericarditis and works by blocking IL-1α and IL-1β, key drivers of inflammation. Kiniksa is also developing Mavrilimumab, which targets GM-CSFRα, for rare cardiovascular diseases, and KPL-404, which targets CD40/CD154, for rheumatoid arthritis. The company's pipeline includes both commercial-stage and clinical-stage assets, reflecting a commitment to addressing serious diseases with innovative immune-modulating therapies. A Phase 2/3 clinical trial is planned for KPL-387, an investigational monoclonal antibody IL-1 receptor antagonist, targeting once-monthly subcutaneous dosing for recurrent pericarditis.
Target Audience
The primary target audience includes patients with inflammatory and autoimmune conditions, particularly recurrent pericarditis and rheumatoid arthritis, as well as healthcare professionals specializing in cardiology and rheumatology.
Features
- ARCALYST® (rilonacept): IL-1α and IL-1β inhibitor approved for recurrent pericarditis.
- KPL-387: Investigational monoclonal antibody IL-1 receptor antagonist in Phase 2/3 clinical trials, designed for once-monthly subcutaneous dosing in a liquid formulation.
- Mavrilimumab: GM-CSFRα targeting antibody being evaluated for development in rare cardiovascular diseases.
- KPL-404: CD40/CD154 targeting molecule in Phase 2 development for rheumatoid arthritis.
- Focus on immune-modulating assets to address the underlying causes of inflammation and autoimmunity.
- Proprietary research and development efforts focused on cardiovascular and autoimmune indications.